SCHEMBL805566

SCHEMBL805566

O=C(c1cc(Nc2nc(-c3ccccc3)nc3ccccc23)[nH]n1)N1CC[C@H](CO)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
AURKA O14965 3/20 0.41
AURKB Q96GD4 3/20 0.41
PAK4 O96013 1/20 0.41
PAK1 Q13153 1/20 0.41
SRC P12931 1/20 0.41
EIF2AK2 P19525 1/20 0.41
ABCC1 P33527 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
KDM5A P29375 6/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NTSR1 P30989 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 2/20 0.41
PDE4B Q07343 1/20 0.41
EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7256154 0.91 RAB9A (0.44) GSK3AGSK3BAURKAAURKBPAK4
SCHEMBL786198 0.91 RAB9A (0.44) GSK3AGSK3BAURKAAURKBPAK4
SCHEMBL13081877 0.89 PAK4 (0.37) PAK4PAK1KDM5AEGFR
SCHEMBL785623 0.82 AURKA (0.52) GSK3AGSK3BAURKAAURKBPAK4
SCHEMBL786587 0.82 LMNA (0.49) GSK3AGSK3BAURKAAURKBSRC
SCHEMBL13055116 0.81 RAB9A (0.40) GSK3BAURKAAURKBPAK4PAK1
SCHEMBL786419 0.78 ABCG2 (0.58) GSK3AGSK3BAURKAAURKBSRC
SCHEMBL786031 0.77 ACP1 (0.51) GSK3AGSK3BAURKAAURKBSRC
SCHEMBL786163 0.76 GSK3A (0.56) GSK3AGSK3BAURKAAURKBSRC
SCHEMBL802574 0.76 MAPK1 (0.53) GSK3AGSK3BAURKAAURKBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed
US-7691853-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-7473691-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-01-06 US disclosed
US-7390815-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A GSK3A 3/4885GSK3B 1/4885AURKA 7/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GSK3A 2/4885GSK3B 1/4885AURKA 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.